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Abstract  Head and neck squamous cell carcinoma pa- 
tients have been characterized by impairments in their 
cell-mediated immune system, particularly by decreased 
chemotactic function of monocytes and impairments in 
the function of the monocyte-derived dendritic cells (viz, 
a decreased capability to form cell "clusters"). These im- 
pairments are thought to be due to immunosuppressive 
factors of low molecular mass released by tumor, the so- 
called pl5E-l ike factors. These suppressive ffects of 
pl5-1ike factors can be neutralized in vitro by thymic pep- 
tides, such as thymostimulin (TP1). In a randomized ou- 
ble-blind, placebo-controlled multicenter t ial in the Nether- 
lands, 41 patients with operable head and neck squamous 
cell carcinomas (HNSCC) were treated for 10 days prior 
to surgery with intramuscular TP1 in one of three dosages 
(0.5 mg/kg; 1.0 rng/kg or 2.0 mg/kg body weight) or treated 
with placebo. Assessment of monocyte chemotaxis, the 
capability of dendritic cells to form clusters and the pres- 
ence of pl5E-l ike low-molecular-mass factors (LMMFs) 
in serum was performed before TP1 treatment and on the 
day of surgery. Findings demonstrated that TP1 in a dose 
of 1.0 mg/kg and 2.0 mg/kg resulted in normalization of 
impaired monocyte chemotactic capability. Although the 
cluster capability of dendritic cells after TP1 treatment 
improved, values only reached statistical significance for 
the 0.5 mg/kg group. Serum pl5E-like LMMF levels were 
J. D. Kerrebijn (r~) 
Department ofOtolaryngology Head and Neck Surgery, 
University Hospital Dijkzigt, Dr. MolewatelTplein 40, 
3015 GD Rotterdam, The Netherlands 
J. D. Kerrebijn -P. J. Simons - H. A. Drexhage 
Department of Immunology, Erasmus University, 
Rotterdam, The Netherlands 
M. Tas 
Department ofClinical Oncology, City Hospital, 
University of Nottingham, Nottingham, UK 
A. J. M. Balm 
Department ofOtolaryngology Head and Neck Surgery, 
The Netherlands Cancer Institute, Amsterdam, The Netherlands 
not affected by TP1 treatment in any of the patient groups. 
Contrary to expectations we found no correlation between 
elevated immunosuppressive LMMFs and defective mono- 
cyte chemotaxis or cluster capability of dendritic cells. 
We conclude that treatment with TP1 can improve mono- 
cyte chemotaxis in HNSCC patients but an effect on the 
production of pl5E-like factors by carcinoma cells could 
not be demonstrated. 
Key words Head and neck carcinoma - Immunotherapy - 
Monocytes • Dendritic cells • Thymostimulin 
Introduction 
Patients with head and neck squamous cell carcinoma 
(HNSCC) may show certain deficits in their immune func- 
tions. The cell-mediated immune system is particularly af- 
fected with defects including T-cell function [20, 24, 44], 
and impaired function of monocytes, monocyte-derived den- 
dritic cells and macrophages [3, 5, 8, 14, 16, 37, 43, 45]. 
We and others have previously reported in detail im- 
pairments of blood monocyte chemotaxis in HNSCC pa- 
tients. These monocyte chemotactic defects are thought o 
be caused by factors of low molecular mass (LMMFs, < 
25 kDa) produced by the cancer cells and appearing in the 
sera of affected patients. These chemotactic defects can be 
mimicked in vivo in animal models as well as in vitro us- 
ing healthy donor monocytes exposed to such tumor-iso- 
lated LMMFs [4, 36, 38]. Since LMMFs show a structural 
and functional homology with transmembrane (TM) pro- 
tein p 15E of animal eukemogenic retroviruses, these sub- 
stances are therefore generally be referred to as "immuno- 
suppressive p 15E-like- or TM-like LMMFs" [9, 38]. 
The function of monocyte-derived, antigen-presenting 
dendritic cells is frequently disturbed in the presence of 
HNSCC. This defect may also be the result of pl5E-like 
LMMFs [43], since such factors in vitro exert a negative 
effect on the ability of dendritic ells to form cellular clus- 
ters. In general, monocyte-derived dendritic ells are class 
II MHC-positive mononuclear cells with long cytoplas- 
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mic extensions that act as excellent accessory cells in im- 
mune responses [2, 13, 19, 26, 35]. 
In an earlier report we demonstrated that abnormal 
monocyte chemotaxis and a defective cluster capability of 
dendritic ells could be restored in vitro by the addition of 
a thymic peptide preparation called thymostimulin (TP1) 
[43]. Clinical trials investigating the effect of  TP1 in var- 
ious malignant disorders have since been carried out. T- 
lymphocyte levels were found to increase in patients with 
malignant melanomas and clinical outcomes could be im- 
proved with adjuvant TP1 treatment [7]. In cases with 
large head and neck cancers overall response to chemo- 
therapy improved if TP1 was used as adjuvant therapy 
[34], while peripheral T-cell counts improved under the 
influence of TP1 in patients with Hodgkin's disease [25]. 
These various observations were the impetus for us to 
conduct a double-blind, placebo-control led multicenter 
study to define in vivo effects of TP1 treatment on mono- 
cyte chemotactic functions, cluster capability of  dendritic 
cells and levels of serum p l5E- l ike  factors in HNSCC pa- 
tients. 
Patients and methods 
Forty-one patients with operable squamous cell carcinoma of the 
oral cavity, oropharynx, hypopharynx or larynx agreed to partici- 
pate in the trial. All patients met the inclusion criteria listed in 
Table 1 and gave informed consent according to university re- 
quirements for human research in The Netherlands. All patients 
were entered randomly in a double-blind fashion in one of the four 
following treatment groups: group I - patients receiving placebo 
treatment; group II -patients receiving 0.5 mg/kg TP1; group III - 
patients receiving 1.0 mg/kg TP1; group IV -patients receiving 
2.0 mg/kg TP1. To avoid investigator bias, TP1 in different 
dosages or placebo was (double-blind) injected intramuscularly in 
each patient once daily for 10 consecutive days prior to definitive 
operation. All injections were well tolerated and no adverse side 
effects were seen. Table 2 summarizes the patients' ages and 
sexes, tumor locations and differentiations, TNM classification 
and subsequent treatment given• No statistical differences were 
found for age, TNM classification or tumor differentiations. 
Bovine thymic extract (TP1) 
Thymostimulin was prepared as a bovine thymic extract using the 
following procedure described by Bergesi and Falchetti [6] and 
Table 1 Inclusion criteria for patients with operable head and 
neck squamous cell carcinomas (HNSCC) for determining effects 
of TP1 treatment on monocyte polarization, dendritic ell cluster- 
ing and serum p15E-like transmembrane factors 
- Untreated squamous cell carcinoma of oral cavity, oropharynx, 
hypopharynx or larynx, with no evidence of metastatic disease 
- Curative treatment possible by surgery or surgery combined 
with radiotherapy 
- No other malignancies 
- White blood count > 4.109/1; platelets > 100.09/1 and hematocrit 
> 30% 
- No serious concurrent non-malignant systemic or infectious 
diseases 
- No treatment with corticosteroids 
Falchetti et al. [ 12]. Calf thymus glands were minced and extracted 
with ammonium acetate. The extract was then heated to 70 ° C, fil- 
tered, and precipitated with ammonium sulfate• The precipitate 
was dissolved in water and subjected to ultrafiltration on an Ami- 
Table 2 Clinical profiles of patients wath HNSCC prior to TP1 
treatment (W well differentiated, M moderately differentiated, P 
poorly differentiated, TL total laryngectomy, CR composite resec- 
tion, P pharyngectomy, PP partial pharyngectomy) 
Pa- Sex Age TNM Local- Differ- Planned 
tients classifi- ization entia- treat- 
cation tion ment 
grade 
Placebo (n = 9) 
1 $ 46 
2 $ 51 
3 c~ 67 
4 d 59 
5 d 45 
6 d 65 
7 c~ 67 
8 c? 45 
9 d 60 
0.5 mg/kg TP1 
10 ~ 62 
11 2 61 
12 d 46 
13 d 56 
14 d 68 
15 d 72 
16 d 52 
17 d 44 
18 d 60 
19 9 74 
1.0 mg/kg TPI 
20 d 61 
21 c~ 45 
22 d 70 
23 d 47 
24 9 56 
25 d 78 
26 $ 65 
27 d 44 
28 $ 52 
29 ~ 66 
30 c~ 56 
31 d 64 
32 d 50 
2.0 
33 
34 
35 
36 
37 
38 
39 
40 
41 
T1NIM0 
T3NOM0 
T3N1M0 
T4N2M0 
T2N1M0 
T4N2bM0 
T4NOM0 
T3N2M0 
T3N2M0 
(n = 10) 
T4NOM0 
T2NOM0 
T2NOM0 
T2NOM0 
T1N2cM0 
T2NOM0 
T3NOM0 
T2NOM0 
T2N2aM0 
T2N1M0 
(n = 13) 
T3N1M0 
T2NOM0 
T3N2M0 
T2N2aM0 
T4N2M0 
T1NOM0 
T3N2bM0 
T2N 1 M0 
T3NOM0 
T4N1M0 
T3N1M0 
T4N1M0 
T4N2M0 
mg/kg TP 1 (n = 9) 
d 67 T4NOM0 
$ 58 T2N2bM0 
d 59 T3NOM0 
d 72 T3N2bM0 
9 61 T2NOM0 
d ~ 51 T3N2cM0 
(5 51 T4N2M0 
49 T3N2bM0 
$ 37 T2NOM0 
Larynx M TL 
oropharynx P CR 
oral cavity W CR 
hypopharnyx P-M TL + P 
oropharynx M CR 
oral cavity M CR 
oral cavity P CR 
oropharynx W CR 
oral cavity P CR 
Oral cavity M CR 
oropharynx M CR 
oral cavity P-M CR 
oral cavity P CR 
larynx M TL 
oral cavity W CR 
oropharynx W CR 
oral cavity P CR 
oropharynx P CR 
oral cavity W CR 
Oropharynx M CR 
oral cavity M CR 
oropharynx M CR 
hypopharynx M TL + PP 
larynx M TL 
oral cavity W CR 
oral cavity M CR 
oral cavity M CR 
oropharynx W CR 
oropharynx W CR 
larynx M TL 
larynx P TL 
hypopharynx P TL + PP 
Oral cavity 
oropharynx 
oropharynx 
oropharynx 
oral cavity 
larynx 
oral cavity 
oropharynx 
oral cavity 
M 
M 
W 
M-W 
M 
M-W 
M-P 
P 
W 
CR 
CR 
CR 
CR 
CR 
TL 
CR 
CR 
CR 
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con PM-10 membrane. The filtrate was desalted on Sephadex G- 
25 and gel-filtered on Sephadex G-50. Fractions showing charac- 
teristic bands at RF 0.22 and 0.24 on polyacrylamide gel elec- 
trophoresIs were combined and termed "thymostimulin" (TP1). 
This extract was next lyophilized and its activity expressed as units 
of T-cell-rosette formation per milligram of protein. No endotoxin 
was contained in this extract, as tested in doses up to 100 mg/kg 
when administered to mice for 21 days or rats for 31 days, or when 
given to cats or dogs for 180 days in doses up to 50 mg/kg [12]. 
Additionally, the extract failed to alter neuromuscular transmission 
in vitro or in vivo [6]. 
Isolation of peripheral blood monocytes 
Peripheral blood mononuclear ceils from patients and healthy con- 
trols were isolated by Ficoll-Isopaque density gradient centrifuga- 
tion. Cells were washed twice in phosphate buffered saline (PBS) 
at pH 7.4, containing 0.5% bovine serum albumin (BSA). Cells 
were then counted in suspension employing positive staining with 
non-specific esterase (NSE) as described by Mullink et al. [29]. 
Monocytes in the Ficoll-Isopaque isolated fraction were enriched 
by Percoll gradient centrifugation [31]. After washing, the Ficoll- 
isolated cell pellet containing both monocytes and lymphocytes 
was resuspended in RPMI 1640 supplemented with 10% fetal calf 
serum (GIBCO, Breda, The Netherlands), 2 mM glutamine and an- 
tibiotics (penicillin and streptomycin), and carefully underlaid 
with an equal volume of Percoll 1.063 (Pharmacia, Uppsala, Swe- 
den). After centrifugation at 400 g for 40 min, all cells were col- 
lected from the interface, washed twice in medium for 10 min and 
counted. This latter suspension ow contained 70-95% NSE-posi- 
rive cells. This suspension was used for direct monocyte polariza- 
tion and maturation to obtain dendritic ells (see below). 
Formation of dendritic ells 
Dendritic cells were prepared from blood monocytes according to 
the method described by Kabel et al. [21]. Metrizamide (Serva, 
Heidelberg, Germany) was dissolved in RPMI supplemented with 
10% fetal calf sea-um. Cells from the isolated monocyte fractions 
were exposed to 14.5% metrizamide in suspension culture for 30 
min (using 5% CO2 at 37°C and 100% humidity). Thereafter, cells 
were washed by slowly adding culture fluid to prevent osmotic ly- 
sis. Cells were then further cultured under non-adhering conditions 
for 16 h in polypropylene tubes (with 5% CO2 and 100% humidity 
at 37 ° C). This procedure yielded 40-80% cells with a dendritic 
morphology, showing class II MHC positivity, decreased expres- 
sion of the monocytic CD14 determinant, decreased phagocytic 
capability, but enhanced stimulator capability in the mixed leuko- 
cyte reaction (MLR). The full technical details of this method are 
described by Kabel et al. [21] and in Mooy et al. [28]. 
Clustering of dendritic ells 
The cluster assay as described by Austyn et al. [2] was performed 
with modifications used by Kabel et al. [21]. Approximately 5 x 
10 ~ dendritic ells prepared from peripheral blood monocytes were 
exposed to metrizamide and allowed to cluster for 4 h in 5% CO2 
at 37°C in 250 gl flat-bottomed wells. Formed clusters were 
counted using an inverted microscope and values were expressed 
as the number of clusters per 6 microscopic fields (x 200). A clus- 
ter was defined as an accumulation of 4-25 cells in three-dimen- 
sional configuration. An insufficient amount of blood was received 
to obtain enough dendritic ells for the cluster assay in 8 cases. 
correlate well with outcomes of the conventional Boyden chamber 
assay to measure chemotaxis to casein [38]. Repeat 0.2 ml aliquots 
of the Percoll or elutriator purified cell suspension containing 
0.2 x 106 monocytes were added to 12-75 mm polypropylene tubes 
(Falcon Labware Division, Becton Dickinson, Oxford, Calif., USA) 
containing 0.05 ml of either medium or formylmethionylleucyl- 
phenylalanine (fMLP) in medium, to reach a final concentration of
10 nM. All experiments were carried out in duplicate. Tubes were 
incubated in a waterbath at 37°C for 15 min. Incubation was 
stopped by addition of 0.25-ml ice-cold 10% formaldehyde in 0.05 
M PBS (pH 7.2). Cell suspensions were kept at 4°C until counted 
in a hemocytometer under a light microscope (magnification, x 
250). Each test was read "blindly" by two persons and 200 cells 
were counted from each tube. A cell was considered to be "polar- 
ized" if one of the following occurred: elongated or triangular 
shapes, broadened lamellipodia or membrane ruffling. 
Chemotactic responsiveness of a monocyte population was ex- 
pressed as the percentage of polarized monocytes in the presence 
of fMLP minus the percentage of polarized monocytes in the ab- 
sence of fMLP. The percentage of polarized monocytes was calcu- 
lated as follows: 
% total cells polarized 
× 100% 
% NSE-positive cells 
Lymphocytes were excluded by their lack of any polarization ac- 
tivity in this assay [9]. 
Determination of p15E-like immunosuppressive factors 
in patients' sera 
Sera for immunological evaluation was collected by venipuncture 
prior to the first injection of TP1 and 1-2 h before surgery. In a 
number of events insufficient sera were received due to logistical 
problems. Sera of healthy hospital staff members erved as control 
sera during all tests. Sera were diluted 1 : 1 in saline and subjected 
to ultrafiltration through Amicon CD25 Centriflo cones (Amicon 
Corp., Danvers, Maine, USA) for 15 rain at 800 g (molecular mass 
"cut-off point", 25 kDa). Residues were resuspended and stored at 
-20 ° C until further use, 
The capability of serum fractions to inhibit fMLP-induced po- 
larization of healthy donor (elutriator-purified) monocytes was de- 
termined by incubating (1 x 106/ml) healthy donor monocytes for 
15 min at 37°C either with fMLP alone or with fMLP in combina- 
tion with a serum fraction (final dilution, 1:60). Details of the 
technique have been described by Tas et al. [43]. The percentage 
of inhibition was calculated as follows: 
i = (1 - (Ff-fo/Mf-fo)) × 100%, where Ff = % monocytes po- 
larized after incubation with fMLP and LMMF; Mf = % monocytes 
polarized after incubation with fMLP alone; and fo = % sponta- 
neously polarized monocytes. 
Spontaneous polarization was not affected by addition of 
serum fractions to non-fMLP stimulated onor monocytes. 
To validate the p 15E-like character of LMMF adsorption, exper- 
iments were carried out by neutralizing serum fractions at 4°C for 
16 h before testing effects on monocyte polarization by using a 
combination of two pl5E-specific mAbs (4F5 and 19F8 as anti- 
p l5E isotypes IgG2a and IgG2b). The final mAb dilution was 1 : 
200 and final IgG concentration 50 gg/ml. Following neutralization, 
Amicon ultrafiltration was performed to remove complexes. The 
adsorption/neutralizing procedure was carried out twice. As con- 
trol antibodies irrelevant anti-human IgG2a and IgG2b were used. 
Statistical analysis 
Monocyte polarization assay 
Statistical analysis was performed using the Wilcoxon signed rank 
test; P < 0.05 was taken as the level of significance. 
The Cianciolo and Snyderman [10] assay for monocyte polariza- 
tion was performed with slight modifications [38] to rapidly test 
monocyte chemotaxis. Outcomes of the assay previously proved to 
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Fig. 1 Serum p15E-like low- 
molecular-mass factor 
(LMMF) levels and monocyte 
polarization before treatment. 
I elevated serum LMMFs and 
depressed monocyte polariza- 
tion; H elevated serum LMMFs 
and normal monocyte polariza- 
tion; I l l  non-elevated serum 
LMMFs and depressed mono- 
cyte polarization; IV non-ele- 
vated serum LMMFs and nor- 
mal monocyte polarization (0 
patients, O healthy controls) 
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Results 
Defects of monocyte polarization 
and dendritic ell clustering capability 
in relation to serum pl5E-like LMMF levels 
Figure 1 shows pretreatment levels of p15E-like LMMFs 
in the sera of individual HNSCC patients in comparison to 
their individual monocyte chemotactic capabilities, Lev- 
els of pl5E-like LMMFs in patient sera were determined 
indirectly by measuring their suppressive effects on 
fMLP-induced monocyte polarization of healthy blood 
donors. 
In the control group of healthy volunteers the mean 
monocyte polarization was 34.2% + 7.9 (n = 23), while 
the mean bioactive inhibitory level of pl5E-like LMMFs 
was 7.3% 5:9.3 (n = 23). Monocyte polarization < 18.4% 
(mean -2 SD) was therefore considered to be defective, 
and LMMF levels > 25.9% inhibition (mean + 2 SD) were 
considered elevated. According to these criteria, 16 pa- 
tients (40%) had defective monocyte polarization, viz 
chemotaxis of lower than 18.4% towards the chemoattrac- 
tant fMLP prior to treatment. Twelve patients (31%) had 
elevated pl5E-like LMMF levels. The patients with de- 
fective monocyte chemotaxis were evenly distributed 
over the group that had normal serum LMMF levels and 
the group that had elevated serum LMMF levels, and no 
correlation was possible between elevated LMMF levels 
and disturbed monocyte chemotactic capability (n = 35, 1" = 
0.018, P > 0.1). 
The mean dendritic cell cluster assay in the healthy 
controls was 133.5 + 42 clusters/6 microscopic fields (n = 
17). A value of less than 92 clusters/6 microscopic fields 
(mean - 1 SD) was considered to be abnormal. According 
to this criterion 16 patients had defective dendritic cell 
clustering capability before treatment. A correlation be- 
tween dendritic cell clustering capability and pl5E-like 
LMMF levels could not be detected (n = 34, r = -0.10, P > 
0.5). Furthermore no correlation existed between dendritic 
cell clustering capability and monocyte polarization (n = 
34, r -- 0.08, P > 0.5). 
Effects of TP1 treatment on monocyte polarization, 
dendritic ell clustering capability 
and serum pl5E-like LMMF levels 
Figure 2a shows fMLP-induced polarization of mono- 
cytes isolated from the blood of HNSSC patients before 
surgery (day 0) and 10 days after surgery (day 10) and ad- 
ministration of either placebo or a TP1 dosage. In all four 
groups the mean initial value (day 0) was markedly lower 
than the 34.2% mean of the polarized monocytes found in 
the healthy control group. 
Treatment with 1.0 mg/kg TP1 resulted in a restoration 
of disturbed monocyte polarization from 17.6% + 6.3 (n = 
13) to a near-normal value of 30.9% + 13.8 (n = 13) at day 
10 (P < 0.01). Similar effects were seen with 2.0 mg/kg 
TP1 (P < 0.05). Monocyte polarization improved to 
32.0% + 15.8 (n = 9) from an initial 17.8% + 18.2 (n = 9). 
Treatment with 0.5 mg/kg TP1 showed no significant im- 
provement (20.9% + 7.0 to 23.0% + 8.1, n = 10). Placebo 
treatment also showed no significant effect on the im- 
paired monocyte polarization (24.0% + 14.2 to 25.7% + 
8.3, n = 9). 
Figure 2b shows the number of clusters formed by 
monocyte-derived dendritic ells from the sera of HNSSC 
patients. At day 0, patients of all four groups showed 
lower values than normal, although this was least marked 
for the placebo group. All three TPl-treated groups 
showed an increase in mean dendritic ell clustering capa- 
bility after treatment (0.5 mg/kg group: 86.0 + 37.0 to 
121.1 + 38.2, n = 9; 1.0 mg/kg group: 99.7 + 34.2 to 116.6 
+ 23.0, n = 11; 2.0 mg/kg group: 98.4 +_ 30.5 to 113.3 5: 
23.0, n = 9). However, only the change in the 0.5 mg/kg 
Fig. 2 a Percentage of formyl- 
methionylleucylphenylalanine 
(fMLP)-induced monocyte po- 
larization before and after 10 
days of TP1 treatment (~) 
placebo, O 0.5 mg/kg TP1, 
[] 1.0 mg/kg TP1, A 2.0 
mg/kg TP 1). b Number of 
dendritic ell-lymphocyte clus- 
ters per 6 microscopic fields 
(x 200) obtained with dendritic 
cells from patient sera before 
and after 10 days of TP1 treat- 
ment. (@ placebo, O 0.5 
mg/kg TP1, [] 1.0 mg/kg TP1, 
A 2.0 mg/kg TP1). e Percent- 
age inhibition of fMLP-in- 
duced polarization of healthy 
donor monocytes by LMMFs 
prepared from patients before 
and after 10 days of TP1 treat- 
ment (~ placebo, O 0.5 rag/ 
kg TP1, [] 1.0 mg/kg TP1, 
2.0 mg/kg TP1) 
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group reached statistical significance (P < 0.05). The 
placebo group showed some decrease in the clustering ca- 
pability of dendritic ells, but this decrease was not statis- 
tically significant. 
Pretreatment levels of pl5E-l ike LMMFs and values 
found after 10 days of TP1 treatment are shown in Fig. 2c. 
No significant changes were found in the levels of serum 
pl5E-l ike factors in group I (0.5 mg/kg, n = 7), group II 
(1.0 mg/kg, n = 15), group III (2.0 mg/kg, n = 9) or pla- 
cebo (n = 9). 
Discussion 
Suppression of cell-mediated immunity in HNSCC is 
thought o be at least partially due to immunosuppressive 
LMMFs produced and released by tumors [9]. These fac- 
tors show a structural homology to retroviral protein 
pl5E. The pl5E-l ike LMMFs and a 17-amino-acid pep- 
tide synthesized from MuLV p l5E (anti-CKS-17) exert a 
suppressive ffect on various immune cells. Suppression 
has been demonstrated in vitro on monocyte chemotactic 
responses [9, 36]; monocyte cytotoxicity by inactivating 
interleukin-1 (IL-1) [15, 22]; the respiratory burst of hu- 
man monocytes [17]; activation of feline neutrophils [23]; 
IL-2- or IL-l-dependent proliferations of T-cells and their 
blastogenic responses to mitogens and allo-antigens [11, 
30, 33], activity of human natural killer (NK) cells [18]; 
polyclonal activation of B-cells [27] and the capability of 
dendritic ells to form clusters per se and with T-cells [32, 
41]. 
The presence of immunosuppressive pl5E-l ike factors 
can be detected in the serum of HNSCC patients via a 
bioassay using healthy donor monocytes. In previous 
studies we showed that removal of a tumor often resulted 
in a postoperative decline of the level of these serum 
pl5E-l ike LMMFs [42], and restoration of monocyte 
chemotactic responsiveness [36]. We assumed that there 
was a direct effect on monocyte chemotaxis by immuno- 
suppressive pl5E-l ike LMMFs produced by tumor and 
circulating in serum, since direct contact between mono- 
cytes and the serum pl5E-l ike factors seemed inevitable. 
Our present data, however, have failed to demonstrate any 
positive correlations between defective monocyte chemo- 
taxis or dendritic ell clustering and serum levels of p 15E- 
like LMMFs. 
An explanation for our present findings may be due to 
heterogeneity in sensitivity of monocytes of individual 
HNSCC patients to immunosuppressive effects of pl5E- 
like factors. It is also possible that other immunomodulat- 
ing factors produced in our patients and stimulating or 
suppressing monocyte chemotaxis may play an additional 
role. A third explanation might be that defective mono- 
cyte polarization and dendritic ell clustering might not be 
a direct result of elevated p 15E-like LMMFs in serum, but 
that these immunosuppressive factors could possibly exert 
such effects as hampered maturation of fully active mono- 
cytes and dendritic cells at the level of the bone marrow. 
In contrast, healthy individuals may have relatively high 
serum levels of pl5E-like LMMFs without showing clin- 
ical or experimental signs of immune suppression [39]. 
Our results do show restoration of defective monocyte 
chemotactic responsiveness in HNSCC patients due to 
treatment with TP1. Treatment with 1.0 mg/kg or 2.0 
mg/kg body weight administered intramuscularly for 10 
consecutive days prior to operation has given near-normal 
values for monocyte responsiveness on the day of opera- 
tion. Statistically, 1.0 mg/kg was found to be the most op- 
timal dose for restoration of the monocyte polarization, 
which has also been reported to be the dose most fre- 
quently used to treat patients with various other disorders 
[1, 7, 40]. An improvement of the dendritic ell clustering 
capability after TP1 treatment was seen for all TP1- 
treated groups; however only in the 0.5 mg/kg group did 
this reach statistical significance. A plausible explanation 
for this may be that the mean pretreatment values of the 
dendritic ell cluster assay of the 1.0 mg/kg and 2.0 mg/kg 
groups were less disturbed than those of the 0.5 mg/kg 
group. Therefore the possible improvement that could be 
achieved was less pronounced. Tas et al. [40] treated pa- 
tients with chronic purulent rhinosinusitis and found a 
similar restorative ffect of TP1 treatment on monocyte 
chemotactic functions accompanied by a concomitant de- 
crease in serum p 15E-like LMMF levels as well as clear 
clinical improvement. 
In our current study, pl5E-like LMMF levels in sera 
from HNSCC patients were unaffected by TP1 treatment. 
These findings suggest hat TP1 counteracts he immuno- 
suppressive effects of pl5E-l ike factors at a cellular level 
and TP1 does not affect production of pl5E-like factors 
by tumor. The decrease in detectable serum LMMF levels 
reported in patients with rhinosinusitis after TP1 treat- 
ment could also be explained by a lower production due to 
improved clinical status, rather than a direct effect of TP1 
on the production or immunosuppressive properties of 
these pl5E-l ike LMMFs. Conclusions concerning clinical 
effects of TP1 in the treatment of HNSCC cannot be 
drawn from our study at this time and will be addressed in
a later report on the long-term results of TP1 treatment. 
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